Psychedelic substances such as esketamine, psilocybin, and MDMA are being reintroduced as potential therapies for severe psychiatric disorders. While some countries have approved esketamine-based antidepressants and substances like MDMA and psilocybin for certain conditions, the evidence supporting these treatments is weak. The unique effects of psychedelics pose challenges in standard double-blind clinical trials, potentially skewing results. Accelerated approvals compromise scientific rigor, and there are concerns about underestimated risks and flaws in scientific articles exaggerating the benefits of psychedelics. Recommendations include stricter regulation and improved clinical trial protocols to ensure the benefits outweigh the risks.
Source link
What does the science say?
